Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, et al. Among authors: rose jw. Neurology. 2001 Dec;57(12 Suppl 5):S16-24. Neurology. 2001. PMID: 11902590 No abstract available.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Johnson KP, et al. Among authors: rose jw. Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268. Neurology. 1995. PMID: 7617181 Clinical Trial.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Among authors: rose jw. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, et al. Among authors: rose jw. Neurology. 2001 Dec;57(12 Suppl 5):S46-53. Neurology. 2001. PMID: 11902595 No abstract available.
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Ford CC, Cohen JA, Goodman AD, Lindsey JW, Lisak RP, Luzzio C, Pruitt A, Rose J, Rus H, Wolinsky JS, Kadosh SE, Bernstein-Hanlon E, Stark Y, Alexander JK. Ford CC, et al. Among authors: rose j. Mult Scler. 2022 Oct;28(11):1729-1743. doi: 10.1177/13524585221094239. Epub 2022 Jun 29. Mult Scler. 2022. PMID: 35768939 Free PMC article. Clinical Trial.
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Voskuhl RR, et al. Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29. Lancet Neurol. 2016. PMID: 26621682 Free article. Clinical Trial.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators. Wynn D, et al. Among authors: rose jw. Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Lancet Neurol. 2010. PMID: 20163990 Clinical Trial.
Vascular function and multiple sclerosis.
Fjeldstad AS, McDaniel J, Witman MA, Ives SJ, Zhao J, Rose JW, Hannon J, Wray DW, Richardson RS. Fjeldstad AS, et al. Among authors: rose jw. J Neurol. 2011 Nov;258(11):2036-42. doi: 10.1007/s00415-011-6065-2. Epub 2011 May 5. J Neurol. 2011. PMID: 21544565
137 results